JNJ stock sentiment todayJohnson & Johnson
Sentiment verdict
Gossip first, financials second — NEUTRAL at 75% confidence.
Last updated · cached analysis, refreshes periodically
JNJ
Johnson & JohnsonA defensive stalwart undergoing a structural shift toward high-growth med-tech and pharma, currently weighed down by persistent legal overhangs.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for JNJ. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by the 'Talco' litigation saga and the post-Kenvue spin-off identity crisis. While the market cheers the focus on high-margin Innovative Medicine, the ongoing multi-billion dollar legal settlements create a ceiling for short-term price appreciation.
- ·Talcum powder litigation settlements
- ·MedTech acquisition spree (Shockwave Medical)
- ·Post-Kenvue spin-off margin expansion
- ·Medicare drug price negotiations (IRA impacts)
Financial
J&J maintains a premier balance sheet with one of the few AAA credit ratings. Removing the consumer health division (Kenvue) has improved top-line growth potential and margins, though it increased reliance on lumpy pharmaceutical R&D and blockbuster performance.
- ·AAA Credit Rating
- ·Dividend King (60+ years of increases)
- ·Forward P/E ~15x
- ·Robust R&D pipeline with 20+ novel therapies by 2030
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders sold a net $61.0M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Uncertainty regarding the finality of the $6.48 billion talc settlement proposal
- ·Patent cliff for blockbuster Stelara starting in 2025
- ·High integration risk from recent multi-billion dollar MedTech acquisitions
Peer temperature
How direct competitors stack up against JNJ right now.
- HOTABBVAbbVie
HOTTER — successfully navigated the Humira patent cliff better than expected with higher earnings momentum.
See full analysis → - NEUTRALMRKMerck & Co.
SIMILAR — dominant oncology portfolio with Keytruda, but facing a similar looming patent cliff as J&J.
See full analysis → - HOTSYKStryker
HOTTER — pure-play MedTech exposure with significantly higher organic revenue growth than J&J's diversified segments.
See full analysis →
- JNJ+0.9%
- ABBV-3.0%
- MRK+13.8%
- SYK-6.1%
Analyst price target
Consensus average of 18 analysts · median 282.00
Source: StockAnalysis.com · updated 2026-08-26
AI-generated analysis for informational purposes only. Not financial advice.